Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients

Table 3 Analysis of clinical features between hepatitis B virus rtCYE/rtCYEI mutation-positive and negative patients, n (%)/median (25^th-75^th percentiles)

	rtCYE/rtCYEI (+) (n = 12)	rtCYE/rtCYEI (-) (n = 28224)	Univariate OR (95%CI)	P value
Age (years)	43 (33-49)	42 (32-51)	3.78 (-7.88-6.95)	0.903
Gender (male)	10 (83.33)	22419 (79.43)	0.77 (0.17-3.53)	1.00
Genotype (A/B/C/D%)	0/0/100/0	0.03/15.11/84.00/0.86		0.515
HBV DNA (log10 IU/mL)	5.37 (3.40-6.69)	4.03 (2.72-6.00)	0.64 (-1.96-0.56)	0.275
ALT (U/L)	65.0 (35.5-151.0)	38.00 (23.0-72.0)	57.48 (-153.95-71.37)	0.473
AST (U/L)	33.0 (29.0-114.5)	35.0 (25.0-66.0)	73.71 (-179.46-109.51)	0.635
TBIL (µmol/L)	13.85 (12.5-21.1)	14.2 (10.2-22.0)	20.32 (-29.46-50.21)	0.610
HBeAg (+)	7 (58.33)	17438 (61.78)	0.87 (0.28-2.73)	0.806
LAM/LdT exposure1	9 (75.00)	15419 (54.63)	0.40 (0.11-1.48)	0.260
ADV exposure1	6 (50.00)	16971 (60.13)	1.51 (0.49-4.68)	0.474
ETV exposure1	1 (8.33)	8698 (30.82)	4.90 (0.63-37.96)	0.169
TDF exposure1	0 (0.00)	390 (1.38)	0.986 (0.98-0.99)	1.000
TAF exposure1	0	0

¹Number of nucleoside/nucleotide analogues (NAs) exposure is counted under inclusion of each NA usage. A drug experience is defined as ≥ 3 months of administration of the drug either alone or in combination with another drug.

(+): Positive; (-): Negative; rtCYE: rtS106C+H126Y+D134E; rtCYEI: rtS106C+H126Y+D134E+L269I; ALT: Alanine aminotransferase; AST: Aspartate transferase; TBIL: Total bilirubin; LAM: Lamivudine; LdT: Telbivudine; ADV: Adefovir dipivoxil; ETV: Entecavir; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide.